Milestone Pharma announces EMA acceptance of MAA for etripamil in PSVT; decision expected Q1 2027

Milestone Pharmaceuticals Inc.

EMA accepted Marketing Authorization Application for etripamil nasal spray (TACHYMIST) for PSVT; decision expected Q1 2027.
Phase 3 RAPID trial: 64% conversion to sinus rhythm at 30 min vs 31% placebo (p<0.001); median time 17 min vs 54 min.
Drug is conditionally approved brand name TACHYMIST in Europe; ~2 million PSVT patients in Europe.
MAA includes global clinical data that supported U.S. FDA approval of etripamil for PSVT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.